Oscient Pharmaceuticals Corporation Acquires Expanded Worldwide Rights To Lead Clinical Candidate Ramoplanin
Published: Feb 08, 2006
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 8, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) and Pfizer Inc subsidiary Vicuron Pharmaceuticals Inc., have restructured the business relationship for Oscient's lead clinical candidate, Ramoplanin, currently in development for the potential treatment of Clostridium difficile-associated disease (CDAD). As part of the new arrangement, Oscient, which previously licensed Ramoplanin from Vicuron for the U.S. and Canada only, acquired worldwide rights and assumes full control of Ramoplanin manufacturing, development and commercialization on a global basis. Oscient recently agreed on a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration for the Phase III program of Ramoplanin.